ClinicalTrials.gg
RecruitingNCT07140393Updated Jun 29, 2026

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

A Phase 1/2 interventional study of HRS-4508+ Capecitabine and HRS-4508+ Trastuzumab in Solid Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 75 years old; Both men and women are welcome;
  2. The mixed cell types need to be confirmed by histology or cytology, and the dominant cell morphology, unresectable or .
  3. ratings of 0 or 1.
  4. Expected survival period ≥ 12 weeks.
  5. At least one outside the central nervous system that meets the v1.1 standard definition.
  6. Willing to participate and comply with the requirements of the research protocol, and willing to cooperate with follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Accompanied by untreated or active central nervous system (CNS) tumor . Subjects with a history of meningeal metastasis or current meningeal metastasis
  2. There have been significant severe infections and major surgeries in the past 4 weeks
  3. Existence of previous or concurrent malignant tumors
  4. Difficult to treat nausea, vomiting, or other gastrointestinal diseases that affect the use of oral medication
  5. Having undergone major surgeries other than diagnosis or within 28 days prior to the first administration;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    HRS-4508+ Capecitabine

    Drug: HRS-4508+ Capecitabine

  • Experimental
    HRS-4508+ Trastuzumab

    Drug: HRS-4508+ Trastuzumab

  • Experimental
    HRS-4508+ Trastuzumab+ Pertuzumab

    Drug: HRS-4508+ Trastuzumab+ Pertuzumab

  • Experimental
    HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel

    Drug: HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel

  • Experimental
    HRS-4508+ Trastuzumab + Nab-paclitaxel

    Drug: HRS-4508+ Trastuzumab + Nab-paclitaxel

  • Experimental
    HRS-4508+ Trastuzumab+ Capecitabine

    Drug: HRS-4508+ Trastuzumab+ Capecitabine

  • Active comparator
    Trastuzumab+ Capecitabine

    Drug: Trastuzumab+ Capecitabine

  • Active comparator
    Trastuzumab+ Pertuzumab

    Drug: Trastuzumab+ Pertuzumab

  • Experimental
    HRS-4508+SHR-A1811

    Drug: HRS-4508+SHR-A1811

Interventions

06

What researchers measure

Primary outcomes

  1. HRS4508 DLT

    Time frame: 3 weeks

  2. HRS4508 MTD

    Time frame: 12 weeks

  3. HRS4508 RP2D

    Time frame: 12 weeks

  4. The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)

    Time frame: 2 years

  5. Objective response rate (ORR)

    Time frame: 1 year

Secondary outcomes

  1. Blood concentrations of HRS-4508

    Time frame: 15 weeks

  2. Blood concentrations of SHR-A1811

    Time frame: 9 weeks

  3. Blood concentrations of Capecitabine

    Time frame: 2 weeks

  4. Objective response rate (ORR)

    Time frame: 1 year

  5. Best overall efficacy (BOR)

    Time frame: 1 year

  6. Duration of response (DoR)

    Time frame: 1 year

  7. Progression free survival (PFS)

    Time frame: 1 year

  8. Disease control rate (DCR)

    Time frame: 1 year

  9. Overall survival (OS)

    Time frame: 2 year

  10. The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)

    Time frame: 2 years

  11. Blood concentrations of Paclitaxel for Injection

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing Municipality 100021, China
    Recruiting
    • Fei Ma · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2025
First posted
Aug 24, 2025
StartActual
Oct 28, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07140393
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Oct 28, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Jiaman Lin
Contact
jiaman.lin@hengrui.com
+86 180 0245 4915
Yadan Huo
Contact
Yadan.huo.yh3@hengrui.com
+86 13381110273

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-4508 · Capecitabine · Trastuzumab · Pertuzumab · Albumin-Bound Paclitaxel · Trastuzumab rezetecan

Start the discussion